# A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

> **NCT06673368** · PHASE2 · TERMINATED · sponsor: **Neurocentria, Inc.** · enrollment: 2 (actual)

## Conditions studied

- ADHD

## Interventions

- **DRUG:** NRCT-101SR, NRCT-202XR

## Key facts

- **NCT ID:** NCT06673368
- **Lead sponsor:** Neurocentria, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-02-25
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-07-15
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06673368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06673368, "A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06673368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*